Previous 10 | Next 10 |
MALVERN, Pa., July 30, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, recently announced that it has adjourned its Special Meeting of Share...
MALVERN, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced that it will report second quarter 2021 financial results on Thursday, August 5, 202...
Baudax Bio Inc. (NASDAQ:BXRX) traded today at a new 52-week low of $0.57. Approximately 620,000 shares have changed hands today, as compared to an average 30-day volume of 2.1 million shares. Baudax Bio Inc. share prices have moved between a 52-week high of $3.94 and the current low of $...
Baudax Bio Inc. (NASDAQ:BXRX) traded today at a new 52-week low of $0.64. Approximately 620,000 shares have changed hands today, as compared to an average 30-day volume of 2.3 million shares. Potential upside of 285.0% exists for Baudax Bio Inc., based on a current level of $0.68 and ana...
Shares of Baudax Bio Inc. (NASDAQ:BXRX) traded at a new 52-week low today of $0.66. Approximately 620,000 shares have changed hands today, as compared to an average 30-day volume of 2.2 million shares. There is potential upside of 284.2% for shares of Baudax Bio Inc. based on a current p...
Baudax Bio Inc. (NASDAQ:BXRX) traded at a new 52-week low today of $0.73. Approximately 620,000 shares have changed hands today, as compared to an average 30-day volume of 1.8 million shares. There is potential upside of 251.8% for shares of Baudax Bio Inc. based on a current price of $0...
MALVERN, Pa., July 01, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced that Glass Lewis & Co., a leading proxy advisory firm, has recommended that Baud...
MALVERN, Pa., June 30, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced that Institutional Shareholder Services, Inc. (“ISS”), the leading gl...
MALVERN, Pa., June 18, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced that it has scheduled a Special Meeting of shareholders to approve its proposed inc...
MALVERN, Pa., June 10, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced Gerri Henwood, the Company’s President and Chief Executive Officer, will par...
News, Short Squeeze, Breakout and More Instantly...
Baudax Bio Inc. Company Name:
BXRX Stock Symbol:
NYSE Market:
Evolv Technologies Holdings Inc. (EVLV) is expected to report $-0.14 for Q4 2023 The Lion Electric Company (LEV) is expected to report $-0.1 for Q4 2023 Fisker Inc. Class A (FSR) is expected to report $-0.2 for Q4 2023 Y-mAbs Therapeutics Inc. (YMAB) is expected to report $-0.19 for Q...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Baudax Bio Inc. (BXRX) is expected to report $-0.53 for Q3 2023